The Innovative Medicines Fund: a universal model for faster and fairer access to new promising medicines or a Trojan horse for low-value creep?
作者信息
Angelis Aris, Aggarwal Ajay, Miners Alec, Grieve Richard, Cairns John, Briggs Andrew
机构信息
Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, WC1H 9SH, UK.
Department of Health Policy and LSE Health, London School of Economics and Political Science, London, WC2A 2AE, UK.
出版信息
J R Soc Med. 2023 Oct;116(10):324-330. doi: 10.1177/01410768231192476. Epub 2023 Aug 24.
Abstract
摘要
相似文献
1
The Innovative Medicines Fund: a universal model for faster and fairer access to new promising medicines or a Trojan horse for low-value creep?
J R Soc Med. 2023 Oct;116(10):324-330. doi: 10.1177/01410768231192476. Epub 2023 Aug 24.
2
Enhancing global access to cancer medicines.
CA Cancer J Clin. 2020 Mar;70(2):105-124. doi: 10.3322/caac.21597. Epub 2020 Feb 18.
3
Access to High Cost Cancer Medicines Through the Lens of an Australian Senate Inquiry-Defining the "Goods" at Stake.
J Bioeth Inq. 2017 Sep;14(3):401-410. doi: 10.1007/s11673-017-9800-2. Epub 2017 Jul 18.
4
Accessibility crisis of essential medicines at Sudanese primary healthcare facilities: a cross-sectional drugs' dispensaries assessment and patients' perspectives.
Int J Equity Health. 2023 Oct 17;22(1):216. doi: 10.1186/s12939-023-02009-y.
5
Improving access to medicines via the Health Impact Fund in India: a stakeholder analysis.
Glob Health Action. 2018;11(1):1434935. doi: 10.1080/16549716.2018.1434935.
6
Access to medicines through health systems in low- and middle-income countries.
Health Policy Plan. 2019 Dec 1;34(Supplement_3):iii1-iii3. doi: 10.1093/heapol/czz119.
7
A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand.
Pharmacoeconomics. 2012 Nov 1;30(11):1051-65. doi: 10.2165/11595270-000000000-00000.
8
Noncommunicable diseases, access to essential medicines and universal health coverage.
Glob Health Action. 2019;12(1):1670014. doi: 10.1080/16549716.2019.1670014.
9
Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods.
Public Health Genomics. 2016;19(3):187-91. doi: 10.1159/000446537. Epub 2016 Jun 1.
10
Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?
Global Health. 2017 Sep 13;13(1):73. doi: 10.1186/s12992-017-0297-6.
引用本文的文献
1
Comparative policy analysis of national rare disease funding policies in Australia, Singapore, South Korea, the United Kingdom and the United States: a scoping review.
Health Econ Rev. 2024 Jun 19;14(1):42. doi: 10.1186/s13561-024-00519-1.
2
Rigour and science in drug regulatory approval.
J R Soc Med. 2023 Oct;116(10):323. doi: 10.1177/01410768231211565.
Zotero 插件